HC Wainwright & Co. Initiates Coverage On AgomAb Therapeutics with Buy Rating, Announces Price Target of $35

Benzinga Newsdesk www.benzinga.com Positive 60.0%

Neg 0% Neu 0% Pos 60%

HC Wainwright & Co. analyst Patrick R. Trucchio initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Buy rating and announces Price Target of $35.